GUTS
Fractyl Health Inc.

1,149
Mkt Cap
$177.14M
Volume
743,200.00
52W High
$3.48
52W Low
$0.825
PE Ratio
-0.65
GUTS Fundamentals
Price
$1.34
Prev Close
$1.39
Open
$1.38
50D MA
$1.14
Beta
1.14
Avg. Volume
5.44M
EPS (Annual)
-$1.44
P/B
-3.67
Rev/Employee
$869.16
Loading...
Loading...
News
all
press releases
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...
PR Newswire·17h ago
News Placeholder
More News
News Placeholder
GUTS Stock Rallied About 28% Today – Here’s Why
Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.
Stocktwits·26d ago
News Placeholder
Fractyl Health Sinks After-Hours On Stock Offering, But Investors Cheer Durable Weight Loss Data
Retail optimism surged following new real-world data showing that patients with advanced type 2 diabetes sustained weight loss and glycemic improvements two years after a single Revita procedure.
Stocktwits·3mo ago
News Placeholder
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company ), a metabolic therapeutics company focused on pioneering new approaches for the treatment of...
Globe Newswire·2y ago
News Placeholder
Fractyl Health reports Q4 EPS ($11.18) vs ($7.39) last year
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Received IDE approval for the Revita Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...
Globe Newswire·2y ago
News Placeholder
Fractyl Health Gains FDA Nod to Investigate Revita Device
Fractyl Health, Inc. (GUTS) just unveiled an update. Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness...
TipRanks Financial Blog·2y ago
News Placeholder
Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval...
Globe Newswire·2y ago
News Placeholder
Fractyl Health receives FDA IDE approval for Revita Remain-1 pivotal study
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Fractyl Health (NASDAQ:GUTS) Stock Price Down 6.2%
Fractyl Health, Inc. (NASDAQ:GUTS Get Free Report)s stock price was down 6.2% during trading on Wednesday . The company traded as low as $7.10 and last traded at $7.20. Approximately...
Zolmax·2y ago

Latest GUTS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.